2012
Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy
Morris PG, Reiner AS, Szenberg OR, Clarke JL, Panageas KS, Perez HR, Kris MG, Chan TA, DeAngelis LM, Omuro AM. Leptomeningeal Metastasis from Non-small Cell Lung Cancer: Survival and the Impact of Whole Brain Radiotherapy. Journal Of Thoracic Oncology 2012, 7: 382-385. PMID: 22089116, DOI: 10.1097/jto.0b013e3182398e4f.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCranial IrradiationDose Fractionation, RadiationFemaleFollow-Up StudiesHumansImage Processing, Computer-AssistedLung NeoplasmsLymphatic MetastasisMaleMeningeal CarcinomatosisMiddle AgedNeoplasm Recurrence, LocalPrognosisRetrospective StudiesSurvival RateConceptsNon-small cell lung cancerWhole brain radiotherapyCell lung cancerLeptomeningeal metastasesTyrosine kinase inhibitorsLandmark analysisIT chemotherapyBrain radiotherapyIntrathecal therapyMedian survivalLung cancerEGFR mutationsEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsMedian age 59 yearsReceptor tyrosine kinase inhibitorsMedian overall survivalAge 59 yearsOptimal therapeutic approachSurvival of patientsDevastating complicationOverall survivalLeptomeningeal carcinomatosisRetrospective reviewRetrospective study
2006
Methotrexate (MTX), procarbazine and CCNU for primary central nervous system lymphoma (PCNSL) in patients younger than 60: Can radiotherapy (RT) be deferred?
Omuro A, Taillandier L, Chinot O, Carnin C, Barrie M, Soussain C, Leblond V, Hoang-Xuan K. Methotrexate (MTX), procarbazine and CCNU for primary central nervous system lymphoma (PCNSL) in patients younger than 60: Can radiotherapy (RT) be deferred? Journal Of Clinical Oncology 2006, 24: 1551-1551. DOI: 10.1200/jco.2006.24.18_suppl.1551.Peer-Reviewed Original ResearchPrimary central nervous system lymphomaHigh-dose chemotherapyProgression-free survivalMedian progression-free survivalOverall survivalComplete responseMaintenance chemotherapySalvage treatmentDay 1Central nervous system lymphomaAcceptable initial approachEffective salvage treatmentGrade 3/4 hematotoxicityMedian overall survivalStem cell rescueFurther treatmentNervous system lymphomaRole of RTIT chemotherapyMedian KPSYounger ptsChemosensitive patientsInduction chemotherapyToxic deathsMedian age